New Products, Emerging Markets Spur Pharmaceutical Growth For Bayer
This article was originally published in The Pink Sheet Daily
During its recent earnings call, the German conglomerate pointed to five drugs recently launched or now awaiting regulatory approval as driving its pharmaceutical sales growth from 2013 to 2015, along with strengthening performance in emerging markets.
You may also be interested in...
Bayer attributes record global sales in its 150-year history to emerging markets and new products such as Xarelto; Teva expands global footprint, and Mylan focuses on its injectables business in emerging markets.
Bayer has filed riociguat, a first-in-class oral soluble guanylate cyclase stimulator, in the U.S. and Europe for approval in both pulmonary arterial hypertension and a related condition, persistent/recurrent chronic thromboembolic pulmonary hypertension. The compound stands to become the first drug therapy approved for CTEPH.
In what's become a crowded field of drugs for advanced prostate cancer, Algeta takes aim at symptomatic bone metastases.